麻豆传媒

Coral Olazagasti, MD is an assistant professor at the Sylvester Cancer Center, University of Miami at Miami, Florida. Dr. Olazagasti developed an interest in lung cancer screening while witnessing that the majority of new referrals during an outpatient oncology elective presented with advanced stages of lung cancer. Being a Latina physician, she is personally invested in ethnic and racial disparities in the medical field and has drawn on her own experiences to highlight the inequities and barriers that minority patients face in healthcare. She hopes to continue to expand her research passions and help close the gap for minorities and vulnerable populations.

---

---

Dr. Pongas is a board certified hematologist and oncologist with clinical experience in indolent and aggressive lymphomas. His research interest is the development of cancer therapeutics for B cell lymphomas and viral associated lymphomas. He has done significant laboratory work in Diffuse Large B cell lymphoma elucidating the therapeutic role of inhibiting various PI3K isoforms. He collaborates with clinical scientists to develop novel therapies in lymphomas and with laboratory scientists to study the mechanism of resistance to the therapies and ways to bypass it. With this approach he hopes to develop combinational therapies and increase the cure rates of various lymphomas.

Jonathan C. Trent, MD, PhD, is professor of medicine, associate director for clinical research, and director of the Bone and Soft-tissue Sarcoma Group at the Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, FL. He earned his undergraduate degree in chemistry at Southeastern Oklahoma State University and his MD and PhD in cancer biology from The University of Texas Health Science Center. He completed an internship and residency in internal medicine at The University of Texas Health Science Center and a fellowship in medical oncology at The University of Texas MD Anderson Cancer Center while serving as chief fellow. Prior to joining the University of Miami Miller, he held appointments as faculty of The University of Texas Graduate School of Biomedical Sciences at Houston and associate professor of medicine in the Department of Sarcoma Medical Oncology, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center in Houston.

Dr. Merchan is a tenured Professor of Medicine in the division of Medical Oncology. He is the Co-leader of the Translational and Clinical Oncology Research Program, the Director of the Phase 1 Clinical Trials Program, and the Associate Director of the NIH funded Calabresi Clinical Oncology Research Career Development Award. As a physician scientist, his contributions to science include redefining the role of the plasminogen activator system in cancer progression, the development of novel preclinical and clinical strategies to overcome resistance in RCC and angiogenesis dependent cancers, and the preclinical and clinical development of tumor and stromal targeted oncolytic viruses and virus-drug combinations. He leads the only academic phase I program in South Florida, bringing novel treatment strategies to many patients with advanced cancer. Dr. Merchan has an established track record in translational cancer research, bringing lab discoveries to the clinic, and has been involved in the development of novel, effective treatment strategies in genitourinary cancers, which resulted in practice changing publications and introduced new treatment options for cancer patients.

Dr. Sagus Sampath is a radiation oncologist in Duarte, California and is affiliated with multiple hospitals in the area, including  and . He received his medical degree from University of California, Irvine, School of Medicine and has been in practice between 11-20 years. Dr. Sagus Sampath accepts Medicare, Blue Cross, United Healthcare - see other .

Sawsan Rashdan, M.D., is an Assistant Professor in the  at UT Southwestern Medical Center. She specializes in treating thoracic malignancies. She is the Director of Thoracic Medical Oncology Clinical Operations.
Dr. Rashdan earned her medical degree at the Faculty of Medicine of Damascus University in Syria. She performed her residency in internal medicine at the Indiana University School of Medicine, where she also completed advanced fellowship training in hematology and oncology.
Certified by the American Board of Internal Medicine in hematology and medical oncology, she joined the UT Southwestern faculty in 2016.
Dr. Rashdan’s research focuses on lung cancer, and she has published a number of academic articles on the subject. She has received funding to pilot a clinical trial to investigate the role of stereotactic ablative radiotherapy (SABR) plus osimertinib as first-line treatment in epidermal growth factor receptor-mutated non-small cell lung cancer. Additionally, she is the Division Quality Officer as well as the Director of Health Equity in the division of hematology and oncology, leading the effort to reduce inequities of health care and increase access of cancer prevention education in minority groups.
Dr. Rashdan also spends time teaching the trainees at UTSW, she leads the lung cancer curriculum for the hematology and oncology fellows at Parkland. In addition to mentoring many fellows, residents, and medical students.
She is a member of several professional organizations, including the American Society of Clinical Oncology, the International Association for the Study of Lung Cancer, and the Dallas County Medical Society as well as American Muslim Women Physicians Association. She is also a member of several committees including: Supporting Women in Achieving Greatness, and Diversity, Equity and Inclusion committee in the Department of Internal Medicine at UTSW.

Briefly, Puneeth Iyengar joined the UT Southwestern Medical Center in Dallas, TX USA in the summer of 2010 and is currently an Assistant Professor of Radiation Oncology, with a professional emphasis on treating lung cancer patients. He is co-leader of the Thoracic Oncology Program in the Harold Simmons Comprehensive Cancer Center, leader of the Lung Radiation Oncology Team, Director of Clinical Research for the Department of Radiation Oncology, and institutional representative to NRG from UT Southwestern. His clinical focus is on studying local therapy for oligometastatic NSCLC. He has published significantly in this area, in top tier journals including JCO, JAMA Oncology, Lancet Oncology, among others. He is overall PI of the international trial NRG LU 002, a randomized phase III study assessing local therapy in the setting of immunotherapy and oligometastatic NSCLC. As a physician scientist, Dr. Iyengar runs an independent laboratory with a focus on studying the complex crosstalk between inflammatory states, cachexia, and lung cancer progression and therapeutic resistance. His research program has been funded by organizations including the National Lung Cancer Partnership, Lung Cancer Research Foundation, and Radiological Society of North America. He has also received a President’s Council Distinguished Researcher Award from UT Southwestern Medical Center at Dallas as well as a Sidney Kimmel Research Foundation Award over the last few years. Finally, he received an American Cancer Society Independent Investigator Research Scholar Award. He received his undergraduate degree from MIT, MD and PhD degrees from the Albert Einstein College of Medicine in New York City, and radiation oncology residency training from MD Anderson Cancer Center in Houston. In addition, he is Board Certified in Radiation Oncology and have been granted medical licensure to practice in Texas.

Jonathan Dowell, M.D., is a Professor in the  at UT Southwestern, and a member of the . He also serves as Chief of Hematology/Oncology at the Dallas VA Medical Center.
Dr. Dowell specializes primarily in thoracic malignancies, including non-small cell and small cell lung cancers, mesothelioma, and thymoma.
Dr. Dowell earned his bachelor’s degree in neuroscience from Amherst College in Massachusetts, where he graduated magna cum laude. He received his medical degree from the University of Chicago’s Pritzker School of Medicine and completed internal medicine residency training at UT Southwestern Medical Center. He then completed advanced training through a fellowship in hematology and oncology at Vanderbilt University in Nashville.
Certified by the American Board of Internal Medicine in hematology and in oncology, Dr, Dowell joined the UT Southwestern faculty in 1996.
Dr. Dowell’s research interests include thoracic malignancies. His investigations have resulted in 40 publications in peer-reviewed journals and contributions to more than 50 book chapters, reviews, editorials, and case reports. Additionally, he has presented his findings at scientific conferences throughout the United States and internationally.
At UT Southwestern, Dr. Dowell chairs the Simmons Cancer Center Data and Safety Monitoring Committee and co-chairs the Dallas VA Transfusion Utilization Committee and the Veterans Integrated Service Network 17 Hematology/Oncology Work Group.
Dr. Dowell is active in several professional societies, including the American Society of Clinical Oncology, the American Society of Hematology, the Texas Medical Association, and the Dallas County Medical Society.

Yuanyuan Zhang, M.D., Ph.D., is an Assistant Professor of Radiation Oncology at UT Southwestern Medical Center specializing in treating lung cancer patients with radiotherapy.
Dr. Zhang earned her medical and doctorate degrees from UT Southwestern. Following graduation, she completed an internship with Memorial Sloan-Kettering Cancer Center and, subsequently, completed her residency at UT Southwestern.
“I like to care for patients and their families in ways that are meaningful and valuable to them by understanding their unique circumstance and challenges, involving them in the decision-making process, and providing the emotional support and care coordination every step along the way – just as I would do for my family members.”
When Dr. Zhang is not in the clinic, she researches ways to improve the effectiveness of radiotherapy in lung cancer in the lab. “We still need better treatments, both increasing the survival rate and quality of life for our patients. To me, staying at the forefront of research presents an element of hope and commitment to our patients.”
Dr. Zhang is a member of the American Society for Radiation Oncology (ASTRO), the Association of Residents in Radiation Oncology, the American Society of Clinical Oncology (ASCO), the American Association for Cancer Research (AACR), the Radiological Society of North America (RSNA), and the Society of Women in Radiation Oncology (SWRO).

Suzanne Cole, M.D., is a medical oncologist at UT Southwestern Medical Center. She serves as the Medical Director of the . She is also Medical Director of the Community Oncology Program at  and Research Leader for the Community Oncology Program.
Dr. Cole earned her medical degree at UT Southwestern, where she also completed her residency in internal medicine. She then received advanced training in hematology and medical oncology through a fellowship at the University of Texas MD Anderson Cancer Center in Houston.
Dr. Cole spent eight years caring for patients in their local communities before she joined the UT Southwestern faculty in 2018.
Board certified in hematology and oncology, Dr. Cole is a Fellow of the American College of Physicians. She is active in a number of cancer-related professional organizations, including the American Society of Clinical Oncology and the American Society of Hematology, and she previously served on the board of the Oklahoma Society of Clinical Oncology. She is the founder of the Hematology & Oncology Women Physician Group.
Dr. Cole has delivered presentations throughout the nation and published articles in peer-reviewed journals covering topics related to cancer and blood-related disorders.

Dr. Marianna Koczywas has been a staff physician at City of Hope Comprehensive Cancer Center since 2001, specializing in thoracic oncology and diseases of the lungs, including .
She is part of the lung cancer and head and neck cancer teams at City of Hope, which is a world leader in the  and research of several serious diseases. The goal is providing patients with the opportunity to live longer and much better lives.
“For patients who have just been told they have cancer, I want them to know there is a place they can come, either for treatment or to get the best opinion,” Koczywas said. “At City of Hope, we have a great team of people where these patients can receive the best possible care.”
Koczywas is the principal investigator in several ongoing , including two specifically involving . She also is an outspoken advocate for combining  with cancer treatment programs early in the process.
She received her degree in 1984 from the Medical Academy of Lodz, in Lodz, Poland, then did a residency at St. Francis Medical Center in Pittsburgh. Koczywas first came to City of Hope for fellowships that included the Department of Medical Oncology & Therapeutics Research and the Department of Hematology/Bone Marrow Transplantation.

Medical Oncology Fellow at UTSW. Interested in lung cancer and immunotherapy research. 

Dr. Arya Amini is a radiation oncologist in Duarte, California and is affiliated with . Dr. Arya Amini accepts Medicare, Blue Cross, United Healthcare - see other .

Dr. Sally York is a medical oncologist and associate professor who treats patients with lung cancer and pleural mesothelioma at the Vanderbilt-Ingram Cancer Center in Nashville, Tennessee.

York doubles as a physician/scientist in the Department of Medicine’s Division of Hematology and Oncology. Her laboratory research has focused on genetics and chemotherapy-induced DNA damage by a defective genomic stability pathway in many tumors.
She also serves as the associate director of the Vanderbilt Medical Scientist Training Program, where she works with upcoming leaders in biomedical research.
York arrived in 2012 after more than a decade at Duke University, where she specialized in lung cancer and was also involved in its Medical Scientist Training Program. York completed both her internal medicine residency and oncology fellowship at Duke.
She earned her M.D. and Ph.D. degrees from Washington University in St. Louis and her Bachelor of Science in biochemistry from the University of Iowa. Her doctorate was in molecular cell biology.

Alok A. Khorana, M.D., F.A.C.P, F.A.S.C.O, is Professor of Medicine, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, the Sondra and Stephen Hardis Chair in Oncology Research, Vice-Chair for Clinical Services of the Taussig Cancer Institute (part of Case Comprehensive Cancer Center) and Director of the Gastrointestinal Malignancies Program at the Cleveland Clinic, Cleveland, Ohio. His clinical and translational research program focuses on predictive factors and drug development in cancer-associated thrombosis and gastrointestinal cancers and has been funded by grants from the National Cancer Institute, the National Heart, Lung, and Blood Institute, the Hardis Family, the Porter Family Fund, VeloSano, the Cleveland Clinic Center for Excellence, the Scott Hamilton CARES Initiative, Stand Up To Cancer (Colorectal Cancer “Dream Team”) and the V Foundation.
Dr. Khorana received his medical degree from Maharaja Sayajirao University’s Medical College in Baroda (now Vadodara, Gujarat), India. His postdoctoral training included a residency in internal medicine at the University at Buffalo in New York and a fellowship in hematology/oncology at the University of Rochester, New York. He is a Fellow of the American College of Physicians and in 2018 was elected Fellow of the American Society of Clinical Oncology.
Dr. Khorana is Past Chair of the American Society of Clinical Oncology (ASCO) Clinical Practice Guidelines Panel (CPGC), Chair of ASCO CPGC’s Pancreas Cancer Working Group, Co-Chair of ASCO CPGC’s Multisite Advisory Group and Co-Chair of the ASCO Guidelines Panel on Resectable Pancreas Cancer. He is currently Chair of the Medical and Scientific Advisory Board of the National Blood Clot Association. He has also served or serves on the ASCO Scientific Program Committee and multiple Guidelines/Guidance Panels.

Dr. Lior Z. Braunstein is a radiation oncologist in New York, New York and is affiliated with . He received his medical degree from Harvard Medical School and has been in practice between 11-20 years. Dr. Lior Z. 

---

Wafik El-Deiry (born, 1961) is an American physician and cancer researcher who is the Associate Dean for Oncologic Sciences at the , , Director of the Cancer Center at Brown University, and the Director of the Joint Program in Cancer Biology at Brown University and its affiliated hospitals. He was previously deputy director of Translational Research at , where he was also co-Leader of the Molecular Therapeutics Program.